The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth
Open accessAbstract
Aptamers, oligonucleotides able to avidly bind cellular targets, are emerging as promising therapeutic agents, analogous to monoclonal antibodies. We selected from a DNA library an aptamer specifically recognizing human epidermal growth factor receptor 2 (ErbB-2/HER2), a receptor tyrosine kinase, which is overexpressed in a variety of human cancers, including breast and gastric tumors. Treatment of human gastric cancer cells with a trimeric version (42 nucleotides) of the selected aptamer (14 nucleotides) resulted in reduced cell growth in vitro, but a monomeric version was ineffective. Likewise, when treated with the trimeric aptamer, animals bearing tumor xenografts of human gastric origin reflected reduced rates of tumor growth. The antitumor effect of the aptamer was nearly twofold stronger than that of a monoclonal anti–ErbB-2/HER2 antibody. Consistent with aptamer-induced intracellular degradation of ErbB-2/HER2, incubation of gastric cancer cells with the trimeric aptamer promoted translocation of ErbB-2/HER2 from the cell surface to cytoplasmic puncta. This translocation was associated with a lysosomal hydrolase-dependent clearance of the ErbB-2/HER2 protein from cell extracts. We conclude that targeting ErbB-2/HER2 with DNA aptamers might retard the tumorigenic growth of gastric cancer by means of accelerating lysosomal degradation of the oncoprotein. This work exemplifies the potential pharmacological utility of aptamers directed at cell surface proteins, and it highlights an endocytosis-mediated mechanism of tumor inhibition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, it has become possible to perform natural selection on oligonucleotides by iterative amplification and selection processes using a technique called systematic evolution of ligands by exponential enrichment, or SELEX.”
From Towards open-ended evolution in self-replicating molecular systems (2017) · cites this paper as [43]
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,421
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,845
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Self-citationInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,667
SELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands
Stoltenburg, R., Reinemann, C., & Strehlitz, B. (2007) · Biomolecular Engineering · doi:10.1016/j.bioeng.2007.06.001 · Cited by 1,485
Analytical applications of aptamers
Tombelli, S., Minunni, M., & Mascini, M. (2004) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2004.11.006 · Cited by 1,020
Dassie, J. P., Liu, X., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 600
Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding
Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., & Miller, D. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26369 · Cited by 407
Cited by
Sorted by citations
Aptamer-Based Detection of Circulating Targets for Precision Medicine
Wu, L., Wang, Y., Xu, X., Liu, Y., Lin, B., Zhang, M., Zhang, J., Wan, S., Yang, C. J., & Tan, W. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01140 · Cited by 706
Nimjee, S. M., White, R. R., Becker, R. C., & Sullenger, B. A. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104558 · Cited by 636
Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy
Sun, H., Zhu, X., Lu, P. Y., Rosato, R. R., Tan, W., & Zu, Y. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.32 · Cited by 541
Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials
Chen, W., Luo, G., & Zhang, X. (2018) · Advanced Materials · doi:10.1002/adma.201802725 · Cited by 382
The biological applications of DNA nanomaterials: current challenges and future directions
Ma, W., Zhan, Y., Zhang, Y., Mao, C., Xie, X., & Lin, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00727-9 · Cited by 351
Metadata
- Authors
- Mahlknecht, G., Maron, R., Mancini, M., Schechter, B., Sela, M., & Yarden, Y.
- Affiliations
- Weizmann Institute of Science (IL)
- Departments of aImmunology and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-04-29
- Volume
- 110
- Issue
- 20
- Pages
- 8170-8175
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3657787
- OpenAlex
- W2062141406
- Cited by
- 169
- References
- 26
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 14 · 2023: 10 · 2022: 16 · 2021: 13 · 2020: 15 · 2019: 14 · 2018: 16 · 2017: 10 · 2016: 8 · 2015: 12 · 2014: 13 · 2013: 1
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA072981, R01CA072981, R37CA072981)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
- Keywords
- DNA aptamers, gastric cancer, lysosomal degradation, receptor tyrosine kinase, endocytosis, tumor growth inhibition, cell surface translocation, aptamer therapeutics
- MeSH terms
- Animals, Antineoplastic Agents, Cross-Linking Reagents, Cytoplasm, DNA, Female, Humans, Lysosomes, Mice, Nude, Neoplasm Transplantation, Nucleotides, Protein Binding, Stomach Neoplasms, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Cell Line, Tumor, Cell Proliferation, Mice, Aptamers, Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
